PharmacoEconomics

, Volume 6, Issue 6, pp 536–552

Costs of Illness in Cost-Effectiveness Analysis

A Review of the Methodology
  • Thomas A. Hodgson
Review Article Cost of Illness in CEA

Abstract

Summary

Costs of illness are an important input in cost-effectiveness analysis (CEA). Reviews of the literature have found that many CEAs are of low technical quality and fail to take accoum of costs of illness appropriately. The costs of illness and disease averted by an intervention, indirect costs, and medical care costs in added years of life arc topics that present methodological issues and are nOt handled consistently in CEAs.

Costs of illness and discase averted may be estimated by prevalence- or incidence- based methods; the correct conceptual paradigm depends on the nature of the disease. Incidence costs may be estimated by modelling the disease process. or directly from prevalence costs. the choice being determined by the extent and quality of data available. Regardless of the method. in forward-looking CEAs potential technological change must be taken into account so that incidence-based lifetime costs estimated from current treatment practices will not be biased.

Whether to include indirect costs is an important issue. because indirect costs may be large and have a significant impact on the cost-effectiveness ratio. In the pure CEA model. indirect costs are excluded on ethical grounds and 10 prevent incursion of elements of cost-benefit analysis into CEA. The modified CEA model accepts enhanced productivity as an economic benefit made possible by, but distinct from. the health effect of an intervention. Indirect costs are included when appropriate, dependi ng on the perspective of the analysis, the measure of effecti veness. and who bears the costs.

When medical care extends life, expenditures will be incurred in the added years for illness and disease unrelated to the intervention. As with indirect costs. the pure CEA considers unrelated ‘downstream’ costs an indirect consequence of the health benefit of the intervention and excludes them from CEAs with the societal perspective. The modified CEA treats unrelated downstream costs as an economic effect of the change in health due to the intervention and includes them in order to have a more complete accounting of the cost of the intervention.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hodgson TA, Meiners MR. Cost-of-illness methodology: a gu ide to curren t practi ces and procedures. Milbank Q 1982; 60: 429–62Google Scholar
  2. 2.
    Fein R. On measuring economic benefit of health programs. In: Veatch RM, Branson R, editors. Ethics and health policy. Cambridge. MA: Ballinger, 1976: 261–87Google Scholar
  3. 3.
    Fein R. Economics of mental illness. New York: Basic, 1958CrossRefGoogle Scholar
  4. 4.
    Weisbrod B. Economics of public health. Philadelphia: University of Pennsylvania Press, 1961Google Scholar
  5. 5.
    Klarman H. Syphilis control programs. In: Dorfman R, editor. Measuring benefits of government investments. Washington, DC: The Brookings Institution, 1965: 367–414Google Scholar
  6. 6.
    Mushkin SJ. Health as an investment. J Political Economy 1962; 70: 5PtGoogle Scholar
  7. 7.
    Rice DP. Estimating the cost of illness. Health Economic Series No 6. Washington, DC: US Government Priming Office. 1966: Pub. No. 947-6Google Scholar
  8. 8.
    The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease, and stroke: a comparative analysis. Am J Public Health 1980; 70: 1249–60Google Scholar
  9. 9.
    Harlunian NS, Smart CN, Thompson MS. The incidence and oxonomic costs of major health impairments. Lexington, MA: Lexingtom Books 1981Google Scholar
  10. 10.
    Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA 1993; 270: 474–8PubMedCrossRefGoogle Scholar
  11. 11.
    Hodgson TA. Cigarette smoking and lifetime medical expenditures. Milbank Q 1992; 70: 81–125PubMedCrossRefGoogle Scholar
  12. 12.
    Max W, Rice DP, MacKenzie EJ. The lifetime cost of injury. Inquiry 1990; 27: 332–43PubMedGoogle Scholar
  13. 13.
    Persson U, Silverberg R, Lindgren B, et al. Direct cost of stroke for a Swedish population. lnt J Terhnol Assess Health Care 1990; 6: 125–37CrossRefGoogle Scholar
  14. 14.
    Winds EH, Hay JW, Gotto Jr AM. Medical Cost of coronary artery disease in the US. Am J Canrdiol 1990; 65: 432–40CrossRefGoogle Scholar
  15. 15.
    Hodgson TA. Annual costs of illness versus lifetime costs of illness and implications of structural change. Drug Information J 1988; 22: 323–41Google Scholar
  16. 16.
    Drummond ME, Stoddan GL, Torrance Gw. Methods for the economic evaluation of health Care programmes. Oxford: Oxford, 1981Google Scholar
  17. 17.
    Lua BR, Elixhauser A. Standards for the socioeconomic evaluation of heahh care services. New York: Springer-Verlag, 1990Google Scholar
  18. 18.
    Thompson MS. Benefit-cost analysis for program evaluation. Beverly Hills, CA: Sage, 1980Google Scholar
  19. 19.
    Klarman HE, Francis JO, Rosenthal GD. Cost effectiveness analysis applied to the treatment of chronic renal disease. Med Care 1968; 6: 48–54CrossRefGoogle Scholar
  20. 20.
    Weinstein MC. Challenges for cost-effectiveness research. Med Decis Making 1986; 6: 194–8PubMedCrossRefGoogle Scholar
  21. 21.
    Weinstein MC. Principles of cost-effective resource allocation in health care organizalions. Int J Technol Assess Health Care 1990; 6: 93–103PubMedCrossRefGoogle Scholar
  22. 22.
    Freund DA, Dittus RS. Principles of pharmacoeconomics analysis of drug therapy. PharmacoEconomics 1992; 1: 20–32PubMedCrossRefGoogle Scholar
  23. 23.
    Patrick DL, Erickson P. Health status and health policy: quality of life in health care evalualion and resource allocation. New York: Oxford, 1993Google Scholar
  24. 24.
    Udvarhelyi IS, Colditz GA, Rai A, et al. Cost-effectiveness and cost-benefit analyses in the medical literature. Ann Intern Med 1992; 116: 238–44PubMedGoogle Scholar
  25. 25.
    Warner KE, Hunon RC. Cost-benefit and cost-effectiveness analysis in health care. Med Care 1980; 18: 1069–84PubMedCrossRefGoogle Scholar
  26. 26.
    Drummond MF. Survey of cost-effectiveness and cost-benefit analyses in industrialized countries. World Health Sial Q 1985; 38: 383–401Google Scholar
  27. 27.
    Johannesson M, Jonsson B. Cost-effeeciveness analysis of hypertension treament - a review of methodological issues. Health Policy 1991; 19: 55–78PubMedCrossRefGoogle Scholar
  28. 28.
    Johannesson M, Junsson B. A review of cost-effectiveness analyses of hypertension treatment. PharmacoEconomics 1992; 1: 250–64PubMedCrossRefGoogle Scholar
  29. 29.
    Holliday SM, Faulds D. Hepatitis B vaccine: a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection. PharmacoEconomics 1994; 5: 141–71PubMedCrossRefGoogle Scholar
  30. 30.
    Drummond M, Brandt A, Luce B, et al. Standardizing methodologies for oconomic evaluation in health care. Int J Technol Assess Health Care 1993; 9: 26–36PubMedCrossRefGoogle Scholar
  31. 31.
    Jöson B. Cost-benefit analysis of hepatitis B vaccination. Postgrad Med J 1987; 63 Suppl. 2: 27–32Google Scholar
  32. 32.
    Groves EJ. Utilization of short-stay hospitals, US, 1985. Vital and Health Statistics Series No. 91. Washington, DC: US Government Printing Office, 1981: DHHS Pub. No. (PHS)87-1752Google Scholar
  33. 33.
    Graves EJ. National Hospital Discharge Survey: annual summary 1991. Vital and Health Statistics Series 13, No. 114, Washington, DC: US Government Printing Office. 1993: DHHS Pub. No. (PHS)93-1175Google Scholar
  34. 34.
    Bennett Jr IL. Technology as a shaping force. Daedalus 1977; 106: 125–33Google Scholar
  35. 35.
    Chrisp P, Lewis NJW, Milne RJ. Simvaslatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease. PharmacoEconomics 1992; 1: 124–45PubMedCrossRefGoogle Scholar
  36. 36.
    Goldman L, Weinstein MC, Goldman PA, et al. Cost effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991; 265: 1145–51PubMedCrossRefGoogle Scholar
  37. 37.
    Hjalle K, Lindgren B, Persson U. Cost-effectiveness of simvastatin versus choicstyrmninc-resul1s for Sweden. PharmcoEconomies 1992; 1: 213–6CrossRefGoogle Scholar
  38. 38.
    Ostcr J, Epstein AM. Primary prevention and coronary heart disease: the economic benefits of lowering serum cholesterol. Am J Public Health 1986; 76: 647–56CrossRefGoogle Scholar
  39. 39.
    Oster J, Epstein AM. Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease - the case of cholestyramine. JAMA 1987; 258: 2381–7PubMedCrossRefGoogle Scholar
  40. 40.
    Schulman KA, Kinosian B, Jacobson TA, et al. Reducing high blood choleslerol level with drugs - cOst-effectiveness of pharmacologic management. JAMA 1990; 264: 3025–33PubMedCrossRefGoogle Scholar
  41. 41.
    Arevalo JA, Washington AE. Cost-effectiveness of prenatal screening and immunizalion for hepatitis B virus. JAMA 1988; 259: 365–9PubMedCrossRefGoogle Scholar
  42. 42.
    Oddone EZ, Cowper PA, Hamillon JD, et al. A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients. Health Serv Res 1993; 28: 97–121PubMedGoogle Scholar
  43. 43.
    Dao TD. Cost-benefit and cost-effectiveness analysis of drug therapy. Am J Hosp Pharm 1985; 42: 791–802PubMedGoogle Scholar
  44. 44.
    Koopmanschap MA, Rutten FH. Indirect costs in economic studies: confronting the cunfusion. PharmacoEconomics 1993; 4: 446–54PubMedCrossRefGoogle Scholar
  45. 45.
    Drummond MF, Davies LM, Ferris III FL. Assessing the cost and benefits of medical research: the diabetic retinopathy study. Soc Sci Med 1992; 34: 973–81PubMedCrossRefGoogle Scholar
  46. 46.
    Ramsey SO, Netttleman MD. Cost-effoctiveness of prophylactic AZT following needleslick injury in health care workers. Med Decis Making 1992; 12: 142–8PubMedCrossRefGoogle Scholar
  47. 47.
    Jönson B, Horisbergcr B, Bruguera M, et al. Cost-benefit analysis of hepatitis-B vaccination. Int J Technol Assess Health Care 1991; 7: 379–402CrossRefGoogle Scholar
  48. 48.
    Russell LB. Is prevention better than cure? Washington, DC: The Brookings Institution, 1986Google Scholar
  49. 49.
    Weinstcin MC. From cost-effectiveness ratios to resource allocation: where to draw the line? In: Sloan FA, editor. Valuing health care-cost, benefits and effectiveness of pharmaceuticals and other medical technologies. New York: Cambridge University Press. In pressGoogle Scholar
  50. 50.
    Nissincn A, Tuomilchto J, Kottke TE, et al. Cost efectiveness of the North Karelia hypenension program 1972-1977. Med Care 1986; 24: 767–80CrossRefGoogle Scholar
  51. 51.
    Johannesson M, Jönsson B. Economic evaluation in healthcare: is there a role for cost-benefit analysis? Health Policy 1991; 17: 1–23PubMedCrossRefGoogle Scholar
  52. 52.
    Kamlet MS. The comparative benefits modding project: a framework for cost-utility analysis of government health care pmgrams. Washington, DC: Department of Health and Human Services, 1992Google Scholar
  53. 53.
    Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989; 5: 559–75PubMedCrossRefGoogle Scholar
  54. 54.
    Drummond M, Torrance G, Mason J. Cost-effective league tables: more harm than good? Soc Sci Med 1993; 37: 33–40PubMedCrossRefGoogle Scholar
  55. 55.
    Krumholz HM, Pasternak RC, Weinstein MC, et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992; 327 (1): 7–13PubMedCrossRefGoogle Scholar
  56. 56.
    Warner KE, Luce BR. Cost-benefit and cost-effectiveness analysis in health care. Ann Arbor, MI: Health Administration Press, 1982Google Scholar
  57. 57.
    Letsch SW, Lazenby HC, Levil KR, et al. National health expenditures. 1991Google Scholar
  58. 58.
    US Bureau of the Census. Statistical abstract of the US 1992. 112th edition. Washington, DC: US Government Printing Office, 1992Google Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Thomas A. Hodgson
    • 1
  1. 1.Office of Analysis, Epidemiology and Health PromotionNational Center for Health Statistics, Centers for Disease Control and PreventionHyattsvilleUSA

Personalised recommendations